A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours

Απλή σελίδα τεκμηρίου
dc.contributor.authorBozionelou, V.en
dc.contributor.authorVamvakas, L.en
dc.contributor.authorPappas, P.en
dc.contributor.authorAgelaki, S.en
dc.contributor.authorAndroulakis, N.en
dc.contributor.authorKalykaki, A.en
dc.contributor.authorNikolaidou, M.en
dc.contributor.authorKentepozidis, N.en
dc.contributor.authorGiassas, S.en
dc.contributor.authorMarselos, M.en
dc.contributor.authorGeorgoulias, V.en
dc.contributor.authorMavroudis, D.en
dc.date.accessioned2015-11-24T19:40:27Z
dc.date.available2015-11-24T19:40:27Z
dc.identifier.issn0007-0920-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24357
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverseen
dc.subjecteffects/pharmacokineticsen
dc.subjectDeoxycytidine/administration & dosage/*analogs & derivatives/pharmacokineticsen
dc.subjectDoxorubicin/administration & dosage/*analogs & derivatives/pharmacologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/*drug therapyen
dc.subjectNeutropenia/chemically induceden
dc.subjectPaclitaxel/*administration & dosage/pharmacokineticsen
dc.subjectPolyethylene Glycols/*administration & dosage/pharmacologyen
dc.subjectSurvival Rateen
dc.titleA dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumoursen
heal.abstractTo determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD), paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours. Twenty-two patients with advanced-stage solid tumours were treated with escalated doses of PLD on day 1 and PCX plus GEM on day 2 (starting doses: 10, 100 and 800 mg m(-2), respectively) every 2 weeks. DLTs and pharmacokinetic (PK) parameters of all drugs were determined during the first cycle of treatment. All but six (73%) patients had previously received at least one chemotherapy regimen. The DLT dose level was reached at PLD 12 mg m(-2), PCX 110 mg m(-2) and GEM 1000 mg m(-2) with neutropaenia being the dose-limiting event. Of the 86 chemotherapy cycles delivered, grade 3 and 4 neutropaenia occurred in 20% with no cases of febrile neutropaenia. Non-haematological toxicities were mild. The recommended MTDs are PLD 12 mg m(-2), PCX 100 mg m(-2) and GEM 1000 mg m(-2) administered every 2 weeks. The PK data revealed no obvious drug interactions. Biweekly administration of PLD, PCX and GEM is a well-tolerated chemotherapy regimen, which merits further evaluation in various types of solid tumours.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1038/sj.bjc.6603832-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17551496-
heal.identifier.secondaryhttp://www.nature.com/bjc/journal/v97/n1/pdf/6603832a.pdf-
heal.journalNameBr J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
Bozionelou-2007-A dose escalation an.pdf
Μέγεθος:
112.68 KB
Μορφότυπο:
Adobe Portable Document Format
Κατεβάστε

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ